Innovative Technology Evonetix’s groundbreaking approach to gene synthesis using semiconductor technology positions it as a leader in high-accuracy, high-speed DNA manufacturing, making it a key partner for organizations needing advanced synthetic biology solutions.

Strong Funding Momentum With recent Series B funding totaling over $54 million from investors like Foresite Capital and Molten Ventures, Evonetix demonstrates significant financial backing and growth potential, indicating opportunities for strategic collaborations and expansion.

Recognition & Awards Winning the Tech Innovation of the Year award at the UK Tech Awards enhances Evonetix’s credibility, making it attractive for enterprise clients seeking proven innovative biotechnology partners.

Leadership & Expertise The company's recent appointment of new CEO Andrew Diston and experienced leadership team, including a Director of Biology promoted to VP roles, highlights a focus on scientific excellence and strategic growth, presenting opportunities for partnership with innovative bio R&D entities.

Market Entry & Positioning Located in Cambridge with a focus on synthetic biology advancement, Evonetix is well-positioned to collaborate with biotech firms, research institutes, and pharmaceutical companies seeking cutting-edge gene synthesis technologies for scalable applications.